BioSpace News Archive

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the appointment of Ankur Dhingra as the company’s new Chief Financial Officer effective March 25, 2021.

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will participate in the following upcoming investor conferences

Sientra, Inc., a medical aesthetics company uniquely focused on plastic surgeons, announced its audited financial results for the fourth quarter and full year ended December 31, 2020.

Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced two poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 10-15, 2021 and May 17-21, 2021.

BeyondSpring, a global biopharmaceutical company focused on the development of innovative cancer therapies, announced that it will host a key opinion leader webinar on Plinabulin, the Company’s lead asset for the prevention of chemotherapy-induced neutropenia on Thursday, March 18, 2021 at 10:00 a.m. Eastern Time.

BARDA to provide funding for the ongoing Phase 3 DISRUPT study of exebacase for the treatment of patients with Staph aureus bloodstream infections

CalciMedica Inc. (“CalciMedica” or the “Company”), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe acute and chronic inflammatory diseases, today announced it has secured a $21 million Series D financing led by Quark Venture LP and GHS Fund (Quark Venture LP and GF Securities) and joined by previous investors,

Intersect ENT, Inc., a global ear, nose and throat medical technology leader dedicated to transforming patient care, announced Neil Hattangadi, M.D., M.Sc. joined the Intersect ENT Board of Directors.

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle ®) technology, today announced that management will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release fourth quarter and full year 2020 financial results on Thursday, March 18, 2021 after the close of market.